Glenmark Pharma Unit Launches Generic Olanzapine Injection in US Market

ELMWOOD PARK, New Jersey — Glenmark Pharmaceuticals Inc., USA, a wholly-owned subsidiary of global pharmaceutical manufacturer Glenmark Pharmaceuticals Limited, announced today the official commercial launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. The rollout introduces an affordable generic equivalent to the institutional healthcare channel, designed to address acute agitation associated with schizophrenia and bipolar I mania in adult patients.

This launch builds upon the firm’s strategic expansion of its sterile injectables portfolio within the United States, targeting acute care facilities, hospitals, and psychiatric treatment units requiring fast-acting intramuscular therapeutic options.

Therapeutic Bioequivalence and Market Dynamics

According to official company statements submitted in regulatory filings to the National Stock Exchange of India (NSE), Glenmark's newly launched Olanzapine for Injection is fully bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zyprexa IntraMuscular Injection, 10 mg/vial, currently held by Cheplapharm Registration GmbH.

Data compiled by healthcare analytics firm IQVIA for the 12-month period ending in May 2026 indicates that the annual market size for Zyprexa IntraMuscular Injection reached approximately $25.4 million. By providing a generic alternative, the company aims to capture institutional market share while optimizing procurement costs for healthcare delivery systems.

Focus on Fast-Acting Institutional Care Portfolio

The introduction of the single-dose vial addresses a critical niche in hospital settings. Unlike oral atypical antipsychotics, intramuscular olanzapine formulations are administered under strict clinical supervision for rapid behavioral control when oral therapy is inappropriate or unavailable.

The company's commercial execution relies heavily on established supply agreements within the US institutional framework, leveraging automated distribution channels to ensure continuous availability to acute care networks.

Official Sources Section

Product approvals, therapeutic data, and commercial volume projections have been verified through official corporate filings distributed via the National Stock Exchange of India Limited and the US Food and Drug Administration (FDA) therapeutic equivalence registers.

Quote Section

Commenting on the commercial rollout, Marc Kikuchi, President and Business Head of North America for Glenmark Pharmaceuticals, stated:

"The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectables portfolio and strengthening our presence within the institutional channel. It reflects our continued commitment to expanding access to quality and affordable treatment options to meet the evolving needs of patients and healthcare providers."

Why It Matters

For hospitals and mental health centers, the arrival of a generic alternative lowers overhead expenses associated with acute psychiatric intervention. For patients and healthcare providers, it ensures a broader, competitive supply chain for a critical, time-sensitive medical countermeasure, decreasing the vulnerability of emergency departments to institutional drug shortages.

Key Facts at a Glance

• Product Launched: Olanzapine for Injection, 10 mg/vial, supplied in a Single-Dose Vial configuration.

• Market Opportunity: Targets a US institutional market valued at approximately $25.4 million annually as of May 2026.

• Reference Drug Equity: Evaluated as fully bioequivalent and therapeutically equivalent to Zyprexa IntraMuscular Injection.

• Primary Indications: Indicated for managing acute agitation associated with adult schizophrenia and bipolar I mania.

FAQ Section

What is the specific indication for Glenmark's Olanzapine for Injection?

The treatment is indicated for the rapid management of acute agitation in adult patients diagnosed with schizophrenia or bipolar I mania. It is designed for intramuscular use inside healthcare institutions.

Is this product identical to the brand-name version?

Yes, regulatory bodies have verified that the product is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa IntraMuscular Injection, 10 mg/vial.

How large is the market sector for this drug?

According to verified IQVIA sales metrics tracking the 12-month trailing cycle ending May 2026, the target US market commands an annual value of approximately $25.4 million.

Source: Glenmark Pharmaceuticals Investor Relations Portal, National Stock Exchange of India Corporate Archive.